Rise and subsequent decline of community-associated methicillin resistant Staphylococcus aureus ST30-IVc in Copenhagen, Denmark through an effective search and destroy policy  by Bartels, M.D. et al.
Rise and subsequent decline of community-associated methicillin
resistant Staphylococcus aureus ST30-IVc in Copenhagen, Denmark
through an effective search and destroy policy
M. D. Bartels1, K. Kristoffersen1, K. Boye1 and H. Westh1,2
1) Department of Clinical Microbiology, Hvidovre University Hospital and 2) Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
Abstract
The number of patients with community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has increased rapidly in
Copenhagen, Denmark since 2003. Patients with the typical Panton–Valentine leukocidin-positive CA-MRSA clone ST30-IVc were con-
tacted with the aim of treating MRSA carriers, evaluating the effect of MRSA eradication therapy (ET), and ﬁnding links among patients.
Twenty-three index patients infected with the ST30-IVc clone from November 2003 to September 2005 were contacted and transmis-
sion chains were studied. The majority of ST30-IVc patients had a connection to the Philippines. Household members were screened
for MRSA and all members of families with MRSA carriers were offered treatment of the carrier state and were followed for 1 year.
MRSA carriers were found in seven of 16 households and transmission occurred among close contacts and in kindergartens. Five days
of ET was insufﬁcient and at least one person in each household was treated with systemic antibiotics. All families were MRSA negative
at 1-year follow-up. The CA-MRSA clone ST30-IVc has been imported to Copenhagen, Denmark, primarily from the Philippines, and
has spread through close contacts and in kindergartens. Treatment of MRSA carriers was difﬁcult and required many resources, but the
clone was eventually successfully eliminated. The import of ST30-IVc to Denmark will continue, but the spread of the clone in Denmark
can be kept to a minimum by direct intervention in the affected families.
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Introduction
The number of patients with community-associated methicil-
lin-resistant Staphylococcus aureus (CA-MRSA) is increasing in
Denmark as well as in other countries [1–4]. Although differ-
ent CA-MRSA clones dominate in different parts of the world,
there are some common features [5]. Usually CA-MRSA
harbours the smaller staphylococcal cassette chromosome
mec (SCCmec) elements IV or V; they are generally not multi-
resistant and often produce the cytotoxin Panton–Valentine
leukocidin (PVL). PVL-positive MRSA strains are associated
with skin and soft tissue infections (SSTI) and necrotizing
pneumonia [4,6]. The PVL-positive clone sequence type (ST)
80-IV is the most prevalent CA-MRSA in Europe [6,7], and in
2001 it was the most common MRSA in Denmark [8].
USA300 (ST8-IV) is the dominant CA-MRSA in the USA [2,9],
whereas ST30-IV has mostly been described in Australasia,
where it is known as the Southwest Paciﬁc clone or the
Western Samoan phage pattern [10,11].
In the community it is often difﬁcult to discover links
among patients. The combination of epidemiological data and
typing of MRSA strains helps to reveal connections between
MRSA patients. We routinely sequence the staphylococcal
protein A (spa) gene and the SCCmec of all MRSA isolates
[12,13]. On a map of Copenhagen the addresses of MRSA
patients with frequent MRSA types are marked with col-
oured pins corresponding to a spa type; according to the
map, the majority of patients with ST30-IVc lived in the same
area of Copenhagen.
In this study all patients infected with the MRSA clone spa
type 019 (t019)-ST30-IVc from November 2003 to September
2005 were contacted. The purpose was to identify associa-
tions among the index cases and to investigate how many of
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them and their closest contacts were MRSA carriers. Further-
more, MRSA-positive families were offered MRSA eradication
therapy (ET) and the effect of treatment was evaluated.
Materials and Methods
Patients
From November 2003 to September 2005 we identiﬁed
MRSA t019-ST30-IVc in 25 patients. The medical doctors at
our department advised the patients’ general practitioner
(GP) on treatment of MRSA infections and carriage. However,
laboratory records showed that follow-up surveillance
cultures were often lacking and that many patients had
recurrent infections. Furthermore, some families had two
GPs, which complicated the coordination of treatment.
Therefore, we agreed with the GPs to conduct the treatment
and follow-up of patients ourselves. In September 2005 the
patients were informed of the project by letter and were
contacted by phone to make an appointment for a home visit.
Home visits
At the ﬁrst home visit, patients were interviewed to investi-
gate how they had acquired MRSA and to ﬁnd a possible
connection among patients. Samples for culture were taken
from all persons living at the same address (nose, throat and
perineum swabs). If no MRSA-positive persons were found,
no further visit was made. In MRSA-positive households all
family members, including non-carriers, were offered free
treatment; they were followed up with home visits and con-
trol samples. The patients were requested to report side-
effects from the treatment and new skin and soft tissue
infections (SSTIs). After each sampling they were informed of
the results, both by letter and by phone, and their GPs were
notiﬁed by letter, along with copies of the culture results.
Structured interview
The following information was sought during a structured
interview:
1 Name of close contacts.
2 Knowledge of other persons with MRSA.
3 Previous MRSA treatment, including treatment of the
carrier state.
4 Risk factors for MRSA acquisition (hospitalization; out-
patient visits; travel outside of Scandinavia; skin disease;
employment in health care facilities, hospitals or institu-
tions; attendance at sports or other activities with many
people).
The name of any child’s school or kindergarten was noted.
Handling of swabs
The swabs taken during home visits were transported in Stu-
art medium, and inoculated in a non-selective enrichment
broth (Statens Serum Institut, Copenhagen, Denmark) for
overnight incubation at 35C. The following day 1 lL of the
broth was cultured on a 5% blood agar plate. Antibiotic discs
(Oxoid Limited, Basingstoke, UK) containing 10 lg of ampicil-
lin, 25 lg colistin sulphate, and 10 lg cefoxitin were placed on
the agar. Ten microlitres of the broth was cultured on an
MRSA ID agar (Biome´rieux, Marcy L’Etoile, France). The plates
were inspected after 24 h and again at 48 h for negative plates.
When MRSA was suspected one colony was streaked onto a
new 5% blood agar plate and incubated overnight at 35C.
From this pure culture a duplex mecA/spa PCR was performed
using a t019-ST30-IVc MRSA as a positive control. If the spa
band had the same size as the positive control, further analy-
ses were not performed. Randomly chosen isolates were spa
typed to determine whether the t019 clone remained stable.
Susceptibility testing
The 25 initial patient isolates were tested on ISOA-agar
(Oxoid Limited) for susceptibility to methicillin, erythromycin,
clindamycin, gentamicin, ciproﬂoxacin, fucidic acid, rifampicin,
and vancomycin by disc diffusion (http://www.srga.org). mecA/
spa duplex PCR, PVL PCR, SCCmec typing, and type IV sub-
typing were performed as previously described [1,12,14].
Multilocus sequence typing was performed on two isolates
[15]. The ﬁnal MRSA isolate from each MRSA carrier was
tested for susceptibility to mupirocin by E-test (AB Biodisk,
Solna, Sweden).
Treatment of MRSA carriage
In an MRSA-positive household, treatment of the carrier
state was offered to all household members. ET was never
attempted during active infection. Standard ET consisted of
whole-body wash and hair wash in 4% chlorhexidine once
daily, combined with mupirocin nasal ointment 2% three
times daily for 5 days. If a 5-day treatment was ineffective,
the chlorhexidine washing was prolonged to 10 days, com-
bined with a 5-day regime of mupirocin. Some throat carri-
ers received systemic antibiotics, either rifampicin 300 mg
three times daily plus fusidic acid 500 mg three times daily
or clindamycin 600 mg three times daily as monotherapy or
in combination with fucidic acid. Two children were treated
with clarithromycin and fucidic acid as oral suspensions. The
medications were free of charge and were delivered directly
to the families, together with written treatment plans. The
treatments were the same as those usually recommended to
MRSA carriers, and no new drugs were introduced. Before
initiation of treatment, the families were requested to clean
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their homes thoroughly, and during treatment towels were
changed daily and bed linen every second day, with a recom-
mendation to launder the linen at >70C.
Follow-up
After each treatment cycle samples for culture were taken
from all household members (nose, throat and perineum
swabs). All families were followed for at least 1 year after
the latest positive MRSA sample.
Results
Participants
Two of the 25 patients, a Filipino couple, had left Denmark.
The remaining 23 agreed to participate. Most patients (96%)
had suffered from SSTIs and some had received antibiotic
treatment from their GP or through a hospital emergency
ward. Fifty-six persons from 16 households were included.
Twenty-six were children. The median age was 31 years
(range 0–59) and the sex distribution was 28 of each sex.
Strain characteristics
The initial MRSA isolates were spa t019, PVL positive and
resistant to b-lactams only. They harboured SCCmec IVc and
were of ST30 (two isolates tested). No MRSA isolates
became mupirocin resistant.
Number of carriers
In nine households (HH) no MRSA carriers were found at
the screening visit. These families had experienced no new
SSTIs and were considered to be MRSA free. Two years
after the screening visit no new MRSA samples had been
received from these nine households. In seven households,
with 27 persons, 15 MRSA carriers were found at the
screening visit (Fig. 1); nine of them were index patients.
Transmission of MRSA
Eight of the 16 households were interconnected and MRSA
carriers were found in six of them (Fig. 1). In ﬁve of the eight
households the parents had emigrated from the Philippines
and three of these families had recently travelled to the Phil-
ippines to visit family. Transmission among children in kinder-
gartens and among close contacts was found. A further six
households had a connection to the Philippines. They had vis-
ited family (two households), had been on a diving holiday
(one household), had a Filipino maid (one household), had
worked in a children’s home in the Philippines (HH9, Fig. 1)
or were close friends of the couple in HH9 (one household).
Two households had no connection to the Southwest Paciﬁc
Region but were connected by being close friends.
Treatment of MRSA carriage
Apart from HH5, all MRSA-positive households accepted ET.
In these six households, 12 of 23 persons (52%) were MRSA
carriers at the screening visit (Fig. 1). Seven were index
patients and ﬁve were new carriers. During follow-up visits
MRSA carriage was found additionally in two of the index per-
sons and three new persons. The treatments and number of
MRSA carriers after each treatment cycle are shown in
Table 1. All patients who received systemic treatment were
throat carriers and some were colonized at all swabbed sites
(male child HH3, mother HH4). Two families (HH3 and HH4)
continued to be MRSA carriers despite several treatments,
FIG. 1. Transmission of MRSA t019 ST30 among 8 households.
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and after 6 months and several ETs the treatment was discon-
tinued. At that time the other four households were MRSA
negative.
One-year follow-up
All six families received a 1-year follow-up visit in 2007. No
MRSA was found in any of the household members and they
had not suffered from SSTIs since the last visit. Interestingly,
methicillin-susceptible S. aureus (MSSA) strains of STs not
related to ST30 (ST1, ST7 and ST45) were found in seven of
nine persons in HH3 and HH4.
From October 2005 to December 2007 MRSA t019-
ST30-IVc was found in 40 patients (25 households) not
included in this project. Our infection control team con-
tacted these families and offered the same programme. Fig. 2
shows the number of t019-ST30-IVc patients in our uptake
area during the period 2003–2007. In 2004, t019 represented
44% of the typical CA-MRSA cases (t008, t019, t044), declin-
ing to 29% in 2007.
Discussion
The ST30-IVc clone is considered a pandemic CA-MRSA
[4,10] and was the most common CA-MRSA in Copenhagen
in 2004 and 2005. We found that ST30-IVc was strongly
connected to the Philippines. Fourteen of the 16 households
either had a direct connection to the Philippines (seven
households) or were part of a transmission chain where
MRSA was introduced from the Philippines (seven house-
holds). Interestingly, a connection between ST30-IVc and the
Philippines has also been found by others [16,17].
The Danish National MRSA guidelines recommend treat-
ment of MRSA carriers with mupirocin nasal ointment and
chlorhexidine baths. The rationale for MRSA decolonization
is to protect the patient from future infections and to stop
transmission of MRSA. This combination therapy has been
TABLE 1. Extended MRSA eradication therapy (ET) in six households
Household
(persons)
Screening
no. of
carriers First ET
Control
no. of
carriers
Second
ET
Control
no. of
carriers Third ET
Control
no. of
carriers
Fourth
ET
Control
no. of
carriers
One year
follow-up
no. of
carriers
HH2 (3) 2 Systemica,
all 10-day
ET
2 10-day ET 0 None 0 None 0
HH3 (4) 1 5-day ET 4 Systemicb,
all 5-day
ET
2 10-day
ETc
2 Systemicb
all 10-day
4 0d
HH4 (5) 3 5-day ET 3 10-day ET 2 Systemice
all 10-day
ET
0 None 0d
HH6 (4) 3 5-day ET 1 Mother
10-day,
others
5-day ET
0 None 1 Systemicf
others
5-day ET
0 0 0
HH8 (5) 2 5-day ETg 0 None 0 None None 0
HH9 (2) 1 Systemich,
both 5-day
ET
0 None 0 None 1 Systemici
both10-day
ET
0 0 0
HH, household; MRSA, methicillin-resistant Staphylococcus aureus.
Household numbers correspond to the numbers in Fig. 1. For details on eradication therapy see Materials and Methods.
Standard systemic treatment for adults: rifampicin and fucidic acid orally for 10 days; children: oral suspensions of fucidic acid and clarithromycin.
aMother and daughter, mother’s treatment changed to clindamycin orally after 6 days due to side-effects.
bSon.
cCompleted only 6 days.
dNot preceded by two negative controls.
eMother, changed to clindamycin orally after 3 days due to side-effects.
fMother 10 days clindamycin orally.
gStopped after 4 days due to skin and soft tissue infections in the mother and youngest son, infections treated with clindamycin orally for 10 days.
hMan.
iMan 10 days clindamycin orally.
FIG. 2. Patients with MRSA t019-ST30 in Copenhagen, Denmark in
2003–2007.
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shown to be effective in a Danish study on ST80 community
MRSA [18]. Other studies on MRSA decolonization, primarily
in hospitalized patients, have reported the effect of mupiro-
cin alone [19], mupirocin and chlorhexidine [20,21], and a
combination of mupirocin, chlorhexidine and systemic antibi-
otics [22]. Often in these studies follow-up periods have
been short [20] or the recolonization rates high [19] and
only two of the studies have included throat sampling
[20,21]. A recent study has shown that repeated ET and
systemic treatment for extranasal sites are effective in MRSA
decolonization [23]. Further studies are necessary to evalu-
ate the long-term effect of decolonization therapy.
Despite several treatment cycles, including systemic anti-
microbial treatment, family members of two households
were still MRSA positive after 6 months. We do not believe
this was due to lack of compliance. The parents had recur-
rent SSTIs and were concerned that their children would
have similar infections. Environmental sampling revealed
MRSA in three of four locations in HH3 [24]. However, it is
still debated whether MRSA in the environment plays a role
in MRSA recolonization [25–27]. The primary reason for the
initial lack of success was probably that two children (male
child, HH3 and youngest female child, HH4) had severe ato-
pic dermatitis, making eradication treatment difﬁcult [28,29].
The male child in HH3 probably transmitted MRSA within
his kindergarten (Fig. 1). When three other boys in the kin-
dergarten had SSTIs, the boy from HH3 was not known to
be a carrier. Because of his direct connection to the Philip-
pines, his parents being MRSA-positive before the outbreak,
and his atopic dermatitis, we believe that he was the origin
of the outbreak. There have not been MRSA outbreaks in
the institution since August 2004, perhaps due to increased
hygiene precautions. The ﬁnding of MSSA strains in seven of
nine persons in HH3 and HH4 at 1-year follow-up shows
that the ST30-IVc strain had been replaced by the MSSA
strains, possibly facilitated by several treatments that had
allowed colonization with MSSA.
Although an ET of 5 days was insufﬁcient in our study,
we cannot conclude that it will be ineffective in other situa-
tions. The purpose of this study was to decolonize families
with recurrent SSTIs, and not to compare different treat-
ment regimens. Therefore, no control group was included,
and the study population was too small to make general rec-
ommendations. Most patients were long-term MRSA carri-
ers, and it is possible that ET would be more efﬁcient if
patients were treated immediately after becoming MRSA
carriers.
Despite systemic treatment of most throat carriers, not
all carriers became MRSA negative. Possible explanations for
the treatment failures could be recolonization from other
HH members or the environment, lack of compliance, colo-
nization of multiple body sites, and skin diseases [30]. Sys-
temic antibiotic treatment of throat carriage has been used
in other studies [31,32].
Eight MRSA carriers were asymptomatic and were recog-
nized only because of screening. They could continue to
spread MRSA if left untreated. Furthermore, household
members who are MRSA negative at screening are at contin-
uous risk of becoming carriers. Therefore, we advocate
decolonization of all household members and not just the
index cases. We experienced no resistance to mupirocin
even after several treatment cycles in some families. We
believe that MRSA in the community can be controlled by a
search and destroy policy [33] and recommend treatment of
MRSA carriers to limit the introduction and spread of MRSA
both in hospitals and in the community.
Our infection control team has continued to contact
new patients (often connected to the Philippines) with the
ST30-IVc clone, and we believe that this is the reason why
ST30-IVc is now sustained at a low level in our uptake
area.
Conclusions
The evolving epidemic of CA-MRSA can be controlled only
if transmission chains are broken. Transmission among
individuals in the community is often difﬁcult to conﬁrm,
but can be elucidated by the combination of typing results,
particularly spa typing, and interviews. Considerable
resources are necessary for a search and destroy policy
for CA-MRSA, but for the time being it seems that this
policy is the best weapon to combat CA-MRSA. The
import of the ST30-IVc clone cannot be stopped, but con-
tinued effort to control this particular clone has shown
that transmission in Copenhagen can be kept to a
minimum by free treatment of individuals with carrier
status, close contact with the families, and follow-up home
visits.
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